![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 40, 30749-30752, October 6, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
§,
¶, and
From the INSERM Unit 530, CNRS, 9 rue Jules Hetzel, 92190 Meudon, France
Fatty acids (FAs)1 are energy-rich
molecules, which play important
metabolic roles. They are also an
integral part of cells as membrane components, which can influence
fluidity and receptor or channel function. Over the past 10 years, it
has become evident that FAs can also act as signaling molecules
involved in regulating gene expression. For the most part, these target
genes encode proteins with roles in FA transport or metabolism. The
corresponding change in the amount of specific proteins is an
adaptative process that the cells develop in response to variations in
FA concentration in the vicinity of the target tissue. Although
interesting progress has been made recently, the mechanism(s) by which
FAs modulate gene transcription still remains largely unresolved. The
purpose of the present review is to address this important issue.
A comprehensive description of FA regulation of gene expression
requires the understanding that 1) FA molecules have a common basic
structure with specific diversity determined by chain length and degree
of unsaturation and 2) FAs are rapidly metabolized.
Long chain FAs (C16 and above) (LCFAs) can be either saturated or mono-
or polyunsaturated (PUFA) depending upon the presence of one or more
double bonds in the polycarbon chain. The most abundant monounsaturated
FA is oleate, in which the chain has 18 carbons and the double bond is
between C9 and C10 from the methyl end (C18:1n-9). The two
major classes of PUFAs are n-3 (or Long chain FAs are insoluble in water and are carried in plasma either
esterified in triacylglycerols arranged in complex structures, the
lipoproteins, or in a non-esterified form (NEFAs) loosely bound to
albumin (Fig. 1). Blood lipoproteins are
synthesized from dietary lipids after absorption and re-esterification
in the intestine (chylomicrons) or the liver (very low density
lipoproteins). Plasma lipoproteins are hydrolyzed by hepatic lipase or
by lipoprotein lipase to produce NEFAs that are locally taken up by the
liver or by muscles and adipose tissue. In contrast, circulating NEFAs are produced almost exclusively by white adipose tissue (WAT) as a
consequence of lipolysis from the stored triacylglycerols during
periods of starvation. In lipogenic tissues like liver and WAT, FAs can
also be synthetized de novo from glucose and esterified.
![]()
INTRODUCTION
TOP
INTRODUCTION
Fatty Acid Structure and...
Overview of Fatty Acid...
Negative Regulation
Positive Regulation
Is PPAR the FA-responsive...
In Search of the...
Conclusion
REFERENCES
![]()
Fatty Acid Structure and Metabolism
TOP
INTRODUCTION
Fatty Acid Structure and...
Overview of Fatty Acid...
Negative Regulation
Positive Regulation
Is PPAR the FA-responsive...
In Search of the...
Conclusion
REFERENCES
3) and n-6
(or
6), named for the carbon involved in the first double bond. The
precursors of these two classes of FAs cannot be synthesized in humans
and must be provided by the diet. Interestingly, n-3
and n-6 PUFAs may have biologically opposite properties,
probably because they give rise to different eicosanoid products. For
instance, when model animals with a propensity to develop tumors are
fed diets containing a large proportion of n-6 PUFAs, tumor
formation is favored, whereas diets with a similar proportion of
n-3 PUFAs are somewhat protective (see Ref. 1 for a review).

View larger version (25K):
[in a new window]
Fig. 1.
Major pathways of fatty acid production,
transport, and metabolism. FA are released by adipose tissue after
lipolysis or by lipoproteins arising either directly from the intestine
after a lipid-rich meal or from the liver. FAs circulate in the plasma
loosely bound to albumin (ALB) and cross plasma membrane
with the help of a FAT (reviewed in Ref. 57). In lipogenic cells like
hepatocytes and adipocytes, they can be synthetized from glucose
(lipogenesis). Inside the cell they bind to a cell-specific cytosolic
FABP and can be exchanged with FAs of membrane phospholipids
(PL). Mainly in liver and adipose tissue they can be
activated into fatty acyl-CoA (FA-CoA) and esterified to
glycerol-3-phosphate to synthesize triacylglycerol. In many cell types,
FAs can be elongated and desaturated by specific enzymes (elongases and
desaturases),
-oxidized in mitochondria or peroxisomes,
-oxidized
in microsomes, peroxidized, or participate in eicosanoid
(prostaglandins, leukotrienes, thromboxanes) synthesis.
Although butyrate, a short chain (four carbon, C4) FA, has been shown
in some cases to exert regulation of specific genes besides its well
known effect on chromatin, most of the reported actions of FAs on gene
expression have been associated with LCFAs. Clearly in the cell, the
signaling molecule is the free FA (not bound to albumin), which is
transported in and out cells with the help of a membrane protein, the
FA transporter (FAT). Six potential FAT candidates, the FA translocase
(FAT-CD36), the FA transport protein, the mitochondrial aspartate
aminotransferase, caveolin, the adipose differentiation-related
protein, and the FA-binding protein (FABP, a cytosolic protein that can
bind to membranes) have been cloned and characterized. In the
cytoplasm, FAs are taken up by a cell-specific FABP and have alternate
destinies (Fig. 1). They can be elongated, desaturated,
-oxidized in
mitochondria or peroxisomes for energy production, submitted to a
peroxidative process or to
-oxidation in microsomes, exchanged with
membrane phospholipids, and participate in or interfere with eicosanoid synthesis. It is, therefore, important to remember that whatever FA
effect is investigated, not only FAs per se but also
products of FA metabolism or FA-sensitive signal transduction cascade
can act as a relay.
| |
Overview of Fatty Acid Regulation of Gene Transcription in Various Organisms |
|---|
|
|
|---|
FA regulation of gene transcription occurs in unicellular and complex organisms. In Escherichia coli, LCFAs are transported and activated as fatty acyl-CoAs catalyzed by FadD, the bacterial acyl-CoA synthetase (ACS). In this organism, CoA derivatives, not FAs, bind with high affinity to a transcription factor, the FaDR, preventing its binding to a response element, thereby allowing the gene involved in FA synthesis (fabA) to be repressed and genes encoding enzymes of FA transport and metabolism (fadL, fadD, fadE, fabBA, fadH) to be induced (reviewed in Ref. 2).
In yeast, it appears that acyl-CoAs are also active in modulating gene
transcription (reviewed in Ref. 2). Studies using Saccharomyces cerevisiae focused on regulation of
the OLE1 gene, which encodes the
-9 desaturase, a
membrane protein that converts saturated palmitoyl (C16:0) and stearoyl
(C18:0) CoA to their monounsaturated counterparts. As expected from the
biological role of the desaturase, the rate of OLE1 gene
transcription is increased in response to exogenous saturated FAs,
whereas exposure to unsaturated FAs sharply reduces transcription
(3). The corresponding positive and negative response elements were
located in the OLE1 upstream promoter region (3); however,
the mechanisms of activation and of repression remain to be elucidated.
In mammals, the expression of many genes has been shown to be modulated
by FAs in a positive or a negative manner. However, in only a few cases
has the transcription rate been clearly demonstrated as the main site
of control. Post-transcriptional regulation can also occur, as
exemplified by the PUFA-induced decrease in stability of stearoyl-CoA
desaturase (SCD1) and glucose transporter 4 (GLUT4) mRNAs in the
adipocytes of the 3T3-L1 cell line (reviewed in Ref. 4). This review
focuses exclusively on the transcriptional aspects of FA control.
Studies reporting mRNA variations in response to FAs without the
demonstration, by run-on or transfection experiments in differentiated
cells, that the rate of transcription is affected are mentioned only
when pertinent.
| |
Negative Regulation |
|---|
|
|
|---|
The control of hepatic lipogenic enzymes is currently the best
example of negative regulation. Thirty years ago, Allmann and Gibson
(5) first observed that feeding mice with linoleate (C18:2n-6) greatly depressed hepatic lipogenesis and
activities of fatty acid synthase (FAS), malic enzyme, and
glucose-6-phosphate dehydrogenase, as would be expected from the
physiology. Surprisingly, however, this effect appeared to be
restricted to PUFAs, because neither palmitate (C16:0) nor oleate
(C18:1n-9) was effective. Following this original
observation, several studies showed that a PUFA-rich diet reduced the
hepatic mRNA levels for FAS, acetyl-CoA carboxylase, L-PK, ATP
citrate-lyase, malic enzyme, SCD1, apolipoprotein A-1 (apoA-1),
the S14 protein (reviewed in Refs. 4 and 6-10), and more recently,
-5 and
-6 desaturases (11, 12).
The work of Clarke, Jump, and their co-workers (13, 14) provided
insight into the mechanism by which FAS and S14 mRNAs are decreased
by PUFAs. Blake and Clarke (13) showed that the reduction in hepatic
FAS and S14 mRNAs following the administration to rats of a
PUFA-rich diet was caused primarily by the inhibition of gene
transcription. In that case, n-3 and n-6 PUFAs
were both effective. This effect was specific because transcription of
the cytosolic phosphoenolpyruvate carboxykinase (PEPCK) (a
gluconeogenic enzyme) and actin genes was not affected by the
treatment. Primary hepatocytes were then used to ascertain the direct
nature of PUFA action (14). Moreover, transfection of hepatocytes with
a chimeric gene containing
4315 to +19 base pairs relative to the
transcriptional start site of the S14 gene linked to the
chloramphenicol acetyltransferase structural gene demonstrated that the
5'-flanking region of the S14 gene was involved (14). The PUFA response
element(s) was located between
220 and
80 base pairs of the S14
promoter (14). The question whether the actual modulators are PUFAs
per se remains open. The observation that prostanoid
inhibitors fail to prevent PUFA action suggests at least that
prostanoids are not involved (14). Because the effect is restricted to
PUFAs and because PUFAs are very sensitive to peroxidation, it is
possible that cytotoxic peroxidative products could be the active
molecules, a still debated issue (15, 16). This would be consistent
with the fact that the effect of PUFA on transcription of genes coding for lipogenic enzymes is restricted to hepatocytes in which
peroxidation occurs. Tissue-specific regulation by PUFA seems to occur
in rat retroperitoneal, but not subcutaneous, WAT (17). In 3T3-L1
adipocytes, arachidonic acid (C20:4n-6) suppressed lipogenic
gene expression by a mechanism requiring cyclooxygenase and
prostaglandin production (18).
Liver-specific transcription of at least two other genes, SCD1
and apoA-1, is also a target of negative
regulation by PUFA (19-21). In the SCD1 gene (and
probably also the SCD2 gene), the PUFA response region has
been located in the promoter. However, the mechanism of
repression is not yet resolved (reviewed in Ref. 4).
| |
Positive Regulation |
|---|
|
|
|---|
Since the initial observation by Amri et al. (22, 23)
that FAs are inducers of the adipocyte lipid-binding protein
(aP2) gene transcription in pre-adipose cells, evidence has
accumulated demonstrating that FAs are potent regulators of the adipose
differentiation process (adipogenesis). From a physiological viewpoint,
it makes sense that FAs induce the expansion of WAT mass after an
excess of food is ingested. Here, in contrast to the situation
described above, saturated and unsaturated long chain FAs (C16 and
longer) are equipotent. Therefore, it seems likely that the mechanism differs from that involved in the negative regulation of the liver lipogenic enzymes. The non-metabolizable FA
-bromopalmitate is also
a strong inducer, suggesting that the metabolism of FAs is not
necessary (24). The enhancement of aP2 gene
expression is slow and is blocked by cycloheximide, indicating that
protein synthesis is required for the induction to occur (22, 23). This
result strongly argues against a direct action of FA on the aP2 gene but is consistent with the possibility that
FAs act by altering the synthesis of either a transcription factor or
of some other protein with a rapid turnover that is required for the
effect (Fig. 2). Indeed, several other
marker mRNAs of the adipocyte phenotype (ACS, FAT, lipoprotein
lipase, GLUT4, the uncoupling protein 2, etc.) are clearly induced by
long term treatment of preadipocytes with FAs.
|
The data discussed above support the idea that FAs stimulate the general adipogenic process but do not give clues to the mechanism. It is possible that a common response element(s) to a FA-responsive master transcription factor is present in the promoter regions of all these genes. One way to decipher the mechanism would be to study in detail the genes when transcription is stimulated by FAs in differentiated adipocytes at a stage when adipogenesis is not occurring. The aP2 and the PEPCK genes meet this criterion (23, 25, 26). PEPCK performs the key function in adipocytes of supplying glycerophosphate, thereby permitting re-esterification of FAs into triglycerides during lipolysis and restraining FA output (27). PEPCK activation also allows esterification of FAs in adipocytes after consumption of a glucose-free, lipid-rich diet. Therefore, a stimulatory action of FAs on PEPCK is physiologically relevant; in agreement with the physiology, glucose inhibits the FA stimulation (25, 26). Using 3T3-F442A adipocytes, it was shown that mono- and polyunsaturated FAs, but not saturated FAs, strongly stimulate accumulation of PEPCK mRNA. This contrasts with the effect of LCFA on aP2 (23) or on carnitine palmitoyltransferase 1 (CPT-1) and liver FABP (L-FABP) in hepatocytes (see below). The effect of FA is rapid, does not require protein synthesis, and acts directly on PEPCK gene transcription. Induction of PEPCK activity follows (10). Neither inhibitors of prostaglandin or leukotriene synthesis nor antioxidants can prevent FA action (28). Although it was initially believed that oleate stimulated PEPCK gene expression in hepatoma cells also (25), it now seems clear that induction of the PEPCK gene by FAs occurs selectively in adipocytes (10). This difference in behavior of the same gene in two tissues may be related to the difference in the function of PEPCK in WAT (glycerogenesis) from that in liver where it is glucogenic.
The expression of a number of genes in the liver is under positive FA
control in a physiologically relevant manner. These include the
acyl-CoA oxidase (AOX), CPT-1, the L-FABP, cytochrome P4504A1, ACS,
3-hydroxy-3-methylglutaryl-CoA synthase, and cholesterol 7
-hydroxylase. To date, the effect of FA on transcription has been
determined for the AOX (21), CPT-1 (29), and L-FABP (30) genes. At
least for the CPT-1 and L-FABP genes, stimulation is restricted to
saturated and unsaturated FAs and requires de novo protein
synthesis (8, 9, 29, 30). Moreover, at least in the case of CPT-1,
recent evidence suggests that inhibitors of FA oxidation and of
eicosanoid synthesis do not prevent induction (8, 29, 31).
Interestingly, CPT-1 and L-FABP genes are also induced by FAs in other
tissues, L-FABP in the small intestine (9), and CPT-1 in the pancreatic
-cell line INS-1 (32). In both cases, saturated and unsaturated
LCFAs have equivalent potencies.
| |
Is PPAR the FA-responsive Transcription Factor? |
|---|
|
|
|---|
The main postulated mechanisms of FA regulation of gene transcription are summarized in Fig. 2. FAs, FA-CoAs, or FA metabolites can: 1) induce a cascade of events leading to a covalent modification of a transcription factor (TF), for instance phosphorylation, thereby altering its transactivation capacity, 2) directly bind to and activate a TF, 3) modify the mRNA stability or 4) influence the transcription rate of a TF, hence 5) changing its de novo synthesis. The FA-responsive TF binds to a recognition sequence, the FA-response element in the promoter-regulatory region of the target gene, either 6) as a monomer or 7) as a homo- or a heterodimer.
Following the cloning in 1990 by Issemann and Green (33) of a new member of the steroid/thyroid receptor superfamily, the so-called peroxisome proliferator-activated receptor (PPAR), the hypothesis that it might be the FA-activated receptor arose. This receptor is activated by the hypolipidemic agents fibrates, peroxisome proliferators (PP), and xenobiotics in a transactivation assay in which recipient cells (usually undifferentiated highly proliferative cells selected for their high transfection efficiency) are co-transfected with a PPAR expression vector and a reporter gene placed under the control of a transcription unit that contains a response element recognized and activated by the receptor. Using such an assay, Gustafsson's laboratory (34) and Wahli's laboratory (35) first showed that FAs are indeed PPAR activators.
The situation became more complex with the discovery of other members
of the PPAR family. At present, three isoforms have been cloned
(PPAR
, -
(=
= NUC1 = FAAR), and -
) with
tissue-specific expression, ligand-specific activation, and the ability
to heterodimerize with retinoid X receptors (RXR), of which three
isoforms (
,
,
) have also been isolated (reviewed in Ref. 36).
A PPAR
2 isoform cloned by Spiegelman and co-workers (37) is
expressed selectively in adipocytes. Retrovirus-mediated ectopic
expression of PPAR
2 in non-adipose NIH-3T3 cells directed adipocyte
differentiation when PPAR activators, like anti-diabetic
thiazolidinediones or polyunsaturated FAs, were provided (38). This
observation suggested that PPAR
2 was the master transcription factor
of the adipocyte lineage. However, PPAR
2 is not expressed in
pre-adipose cells, and
-bromopalmitate, an inducer of
differentiation, is an inefficient transactivator of PPAR
. Hence,
the hypothesis that FAAR (PPAR
) could play such a role has been
proposed and is still a matter of debate (39).
The final evidence that FAs are ligands for the three PPARs came in
1997 (40-42). Using various methods to estimate binding, some
corroborative specificity was shown among FAs, PUFAs being much better
ligands than saturated FAs except for PPAR
, to which palmitate
(C16:0) bound with good affinity. Of particular interest also was the
observation that specific prostaglandins and leukotrienes are PPAR
activators (reviewed in Ref. 36). The
15-deoxy-
12,14-prostaglandin J2 (15d-PGJ2), an
arachidonic acid (C20:4n-6) metabolite of the PGD2-J2
series, is a very potent and specific PPAR
ligand. The
lipoxygenation product of arachidonate,
(8S)-hydroxyeicosatetraenoic acid, is the most potent
PPAR
activator in a transactivation assay. The leukotriene B4 is a
PPAR
-specific activating ligand. Carbaprostacyclin, a stable
analogue of prostacyclin, activates PPAR
and PPAR
. Therefore, all
these molecules could be second messengers for FA transcriptional
action. This would imply, however, that they are produced by the cells
in which FAs are directly acting, a debated issue.
Using the transactivation assay described in Ref. 10, PP
response elements (PPREs) have been identified in a number of genes. They consist of imperfect versions of a direct repeat of the AGGTCA consensus sequence separated by one nucleotide (DR1) to which the
additional 5'-extended portion AACT appears to be important for
polarity and selectivity of recognition (reviewed in Ref. 36). Such an
element is able to bind PPAR/RXR heterodimers in a gel retardation
assay. A degenerate AGGTCA is also the half-site recognition sequence
for the 9-cis- and all-trans-retinoic acids, thyroid hormone, vitamin D subclass of nuclear receptors and orphan receptors like hepatic nuclear factor 4 (HNF4), and chicken ovalbumin upstream promoter transcription factor (reviewed in Ref. 36). A number
of genes shown to be FA-responsive respond also to PPAR activators and
present a PPRE in their promoter-regulatory regions. Hence, it has been
assumed that FAs regulate gene transcription via a PPAR/PPRE-mediated
process (reviewed in Ref. 43). This is the case for instance with AOX,
ACS, apoA-1, aP2, CPT-1, L-FABP, SCD1, S14, and PEPCK. This
non-exhaustive list can be found in positively and negatively
FA-regulated genes. However, recent evidence suggests that alteration
of gene transcription by FAs and PPAR activators is often disconnected.
Some genes that contain a PPRE do not respond to FAs, as is the case
with, for instance, apoA-II in primary hepatocytes (21) or FAT-CD36 in
differentiated adipocytes.2
Moreover, PUFAs repress transcription of the
-5 and
-6
desaturases (11, 12), whereas the same genes are induced by PPAR
activators. LCFAs, but not PP, induce CPT-2 in fetal rat hepatocytes
(29). Fibrate induction of CPT-1 gene expression is impaired by
lipoxygenase inhibitors in hepatocytes, whereas the FA effect is
maintained (8); the PEPCK gene promoter-regulatory region contains two DR1-like sequences able to bind a PPAR/RXR heterodimer in a gel shift
assay (44). It is responsive to FAs in adipocytes but not in
hepatocytes or hepatoma cells (see above), which, however, contain
large amounts of PPAR
. In the S14 gene, the
cis-regulatory negative element for the PPAR
-specific
ligand wy14643 is clearly distinct from that for PUFAs (45).
These conclusions were reinforced with the analysis of
PPAR
-deficient mice. In such animals, the administration of fish oil in vivo or the addition of PUFAs to cultured hepatocytes
repressed S14 and FAS gene expression although induction of AOX and
CYP4A2 mRNAs was abolished (46). Other studies demonstrated that
negative regulation of the L-PK gene by PUFA is independent of PPAR
and that the PPAR
/RXR
heterodimer does not bind the L-PK promoter (47). Hence, some of the FA effects, but certainly not all, can be
assigned to PPAR activation.
| |
In Search of the FA-responsive Transcription Factors: Other Candidates |
|---|
|
|
|---|
Several lines of evidence indicate that transcription factors different from the PPARs could mediate FA effect. As mentioned above, other proteins recognize DR1-like sequences. Among these, the orphan hepatic receptor HNF4 was shown to bind FA-CoA (48). In transient transfection in recipient cells, oleate and PUFAs inhibited HNF4 transactivation potential of the human apolipoprotein CIII gene promoter governing chloramphenicol acetyltransferase expression. Among saturated FAs, medium and short chain had no effect, palmitate was stimulatory, and stearate (C18:0) was inhibitory. Whether this observation has any physiological relevance remains an open question. Last but not least, in chick hepatocytes, it was shown that medium chain FAs can alter triiodothyronine or estrogen action without interfering with the binding of the respective receptors to their cognate DNA elements (49).
Another route that FA could follow to regulate gene transcription would
be to alter the de novo synthesis of a TF as shown in step 5 of Fig. 2. There are three recent examples of this possibility. One is
related to the PUFA inhibition of lipogenic genes. Because of
similarities between the negative feedback control by FA and cholesterol of their respective biosynthetic pathways, Worgall et
al. (50) analyzed the effects of PUFA on genes having sterol regulatory elements (SRE) in their promoter-regulatory regions. In
transfected cells they found that oleate and PUFAs reduced expression
of SRE-containing genes by decreasing the level of SRE-binding protein
(SREBP). Saturated FAs were ineffective, a situation reminiscent of
what was shown for the PEPCK gene regulation in adipocytes. It was
later reported that PUFAs decrease SREBP1 gene expression and nuclear
content of SREBP1 in liver and in primary hepatocytes but not in 3T3-L1
adipocytes (51, 52). Because SREBP1 is a positive effector of the FAS
and S14 lipogenic genes, the reduction in quantity of SREBP1 accounts
for the FA inhibition. This observation is corroborated by results of
experiments with transgenic mice either overexpressing SREBP1 (53) or
knocked out for this gene (54). Interestingly, the action of PUFAs on SREBP1 is post-transcriptional as exemplified by step 3 in Fig. 2, but
the mechanism has not been alleviated yet. Another report describes the
induction of the immediate-early response genes c-fos and
nur-77 in the pancreatic
-cell line INS-1 by palmitate and oleate but not by PUFAs (55). In this situation, FA affects the
gene transcription rate (step 4 in Fig. 2). Moreover, this induction
was mediated by certain isoforms of protein kinase C and required
elevated calcium (55), corresponding to step 1 in Fig. 2. In the
third report, the response of the liver X receptor-
(LXR
) to FAs
has been studied (56). Treatment of rat hepatoma cells or primary
hepatocytes with unsaturated FAs induces an increase in LXR
protein,
mRNA, and gene transcription. Because LXR
is a nuclear receptor
thought to be an important regulator of cholesterol, steroid hormone,
and bile acid catabolic pathways, the observation that it is
FA-responsive suggests that it plays a role in the cross-talk between
FA and cholesterol regulation of lipid metabolism. In the case of
SREBP, c-fos, nur-77, and LXR
, FAs modulate
the amount of transcription factors potentially acting as regulators of
the expression of genes, which code for proteins having a metabolic role.
| |
Conclusion |
|---|
|
|
|---|
It seems clear that depending upon the specific cell context and
target gene, FAs can use very different routes to alter transcription. Although the details of exact mechanisms are still needed, rapid progress have been made recently, particularly with the help of mutant
mice in which specific transcription factors or nuclear receptors were
either overexpressed or deleted by knockout. In vivo studies
using such animal models and analysis of specific cell types derived
from these mice would permit the identification of the targeted protein
as a FA-responsive regulator. One reason that the exact mechanism has
been so difficult to decipher may be related to the complexity of
chromatin structure that adds to the task of integrating selective
signals in the rapidly growing network of recently discovered
coregulators acting on histone acetylation and altering the
transcriptional activity of specific nuclear proteins. Because it is
now recognized that plasma FA concentration and identity have profound
effects on metabolism, linking nutrition to obesity, diabetes,
cardiovascular diseases, and cancer, it is of great value to actively
elucidate the mechanisms by which these molecules alter gene transcription.
| |
FOOTNOTES |
|---|
* This minireview will be reprinted in the 2000 Minireview Compendium, which will be available in December, 2000. This is the first article of three in the "Nutrient Control of Gene Transcription Minireview Series." This work was supported by grants from INSERM, CNRS, and "Fondation pour la Recherche Médicale."
Recipients of a fellowship from the French "Ministère de
l'Education Nationale et de la Recherche." These two authors
contributed equally to this work.
§ Recipient of the 2000 Award from the "Institut Danone."
¶ Recipient of the 1999 Award from the "Association Française de Nutrition-Société de Nutrition de Langue Française."
A research director with INSERM. To whom correspondence should
be addressed. Tel.: 33 1 45 07 50 70; Fax: 33 1 45 07 58 90; E-mail:
forest@cnrs-bellevue.fr.
Published, JBC Papers in Press, August 8, 2000, DOI 10.1074/jbc.R000015200
2 E. Duplus, M. Glorian, and C. Forest, unpublished results.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: FA, fatty acid; LCFA, long chain fatty acid; PUFA, polyunsaturated fatty acid; NEFA, non-esterified fatty acid; WAT, white adipose tissue; FAT, fatty acid transporter; FABP, fatty acid-binding protein; L-FABP, liver FABP; ACS, acyl-CoA synthetase; SCD1, stearoyl CoA desaturase 1; L-PK, liver-type pyruvate kinase; apoA-1, apolipoprotein A-1; FAS, fatty acid synthase; PEPCK, cytosolic phosphoenolpyruvate carboxykinase; CPT-1, carnitine palmitoyltransferase; AOX, acyl-CoA oxidase; TF, transcription factor; PP, peroxisome proliferator(s); PPAR, peroxisome proliferator-activated receptor; PPRE, peroxisome proliferator-response element; DR1, direct repeat 1; RXR, retinoid X receptor; PG, prostaglandin; HNF-4, hepatic nuclear factor 4; SRE, sterol regulatory element(s); SREBP, SRE-binding protein; LXR, liver X receptor.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Cave, W. T., Jr. (1991) FASEB J. 5, 2160-2166 |
| 2. | Black, P. N., Faergeman, N. J., and DiRusso, C. C. (2000) J. Nutr. 130 (suppl.), 305S-309S |
| 3. | Choi, J. Y., Stukey, J., Hwang, S. Y., and Martin, C. E. (1996) J. Biol. Chem. 271, 3581-3589 |
| 4. | Sessler, A. M., and Ntambi, J. M. (1998) J. Nutr. 128, 923-926 |
| 5. | Allmann, D. W., and Gibson, D. W. (1969) J. Lipid Res. 6, 51-62 |
| 6. | Clarke, S. D., and Jump, D. B. (1994) Annu. Rev. Nutr. 14, 83-98 |
| 7. | Jump, D. B., and Clarke, S. D. (1999) Annu. Rev. Nutr. 19, 63-90 |
| 8. | Pegorier, J. P. (1998) Curr. Opin. Clin. Nutr. Metab. Care 1, 329-334 |
| 9. | Niot, I., Poirier, H., and Besnard, P. (1997) Biochimie (Paris) 79, 129-133 |
| 10. | Forest, C., Franckhauser, S., Glorian, M., Antras-Ferry, J., Robin, D., and Robin, P. (1997) Prostaglandins Leukotrienes Essent. Fatty Acids 57, 47-56 |
| 11. | Cho, H. P., Nakamura, M. T., and Clarke, S. D. (1999) J. Biol. Chem. 274, 471-477 |
| 12. | Cho, H. P., Nakamura, M., and Clarke, S. D. (1999) J. Biol. Chem. 274, 37335-37339 |
| 13. | Blake, W. L., and Clarke, S. D. (1990) J. Nutr. 120, 1727-1729 |
| 14. | Jump, D. B., Clarke, S. D., MacDougald, O., and Thelen, A. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8454-8458 |
| 15. | Mikkelsen, L., Hansen, H. S., Grunnet, N., and Dich, J. (1993) Biochim. Biophys. Acta 1166, 99-104 |
| 16. | Foretz, M., Foufelle, F., and Ferre, P. (1999) Biochem. J. 341, 371-376 |
| 17. | Raclot, T., Groscolas, R., Langin, D., and Ferre, P. (1997) J. Lipid Res. 38, 1963-1972 |
| 18. | Jump, D. B., Thelen, A., and Mater, M. (1999) Lipids 34 (suppl.), S209-S212 |
| 19. | Ntambi, J. M. (1992) J. Biol. Chem. 267, 10925-10930 |
| 20. | Landschulz, K. T., Jump, D. B., MacDougald, O. A., and Lane, M. D. (1994) Biochem. Biophys. Res. Commun. 200, 763-768 |
| 21. | Berthou, L., Saladin, R., Yaqoob, P., Branellec, D., Calder, P., Fruchart, J.-C., Denefle, P., Auwerx, J., and Staels, B. (1995) Eur. J. Biochem. 232, 179-187 |
| 22. | Amri, E. Z., Ailhaud, G., and Grimaldi, P. (1991) J. Lipid Res. 32, 1457-1463 |
| 23. | Amri, E. Z., Bertrand, B., Ailhaud, G., and Grimaldi, P. (1991) J. Lipid Res. 32, 1449-1456 |
| 24. | Grimaldi, P. A., Knobel, S. M., Whitesell, R. R., and Abumrad, N. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10930-10934 |
| 25. | Antras-Ferry, J., Lebigot, G., Robin, P., Robin, D., and Forest, C. (1994) Biochem. Biophys. Res. Commun. 203, 385-391 |
| 26. | Antras-Ferry, J., Robin, P., Robin, D., and Forest, C. (1995) Eur. J. Biochem. 234, 390-396 |
| 27. | Reshef, L., Hanson, R. W., and Ballard, F. J. (1970) J. Biol. Chem. 245, 5979-5984 |
| 28. | Glorian, M., Duplus, E., and Forest, C. (1999) Chem. Phys. Lipids 101, 141-142 |
| 29. | Chatelain, F., Kohl, C., Esser, V., McGarry, J. D., Girard, J., and Pegorier, J.-P. (1996) Eur. J. Biochem. 235, 789-798 |
| 30. | Meunier-Durmort, C., Poirier, H., Niot, I., Forest, C., and Besnard, P. (1996) Biochem. J. 319, 483-487 |
| 31. | Kaikaus, R. M., Sui, Z., Lysenko, N., Wu, N. Y., Ortiz de Montellano, P. R., Ockner, R. K., and Bass, N. M. (1993) J. Biol. Chem. 268, 26866-26871 |
| 32. | Assimacopoulos-Jeannet, F., Thumelin, S., Roche, E., Esser, V., McGarry, J. D., and Prentki, M. (1997) J. Biol. Chem. 272, 1659-1664 |
| 33. | Issemann, I., and Green, S. (1990) Nature 347, 645-650 |
| 34. | Gottlicher, M., Widmark, E., Li, Q., and Gustafsson, J. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 4653-4657 |
| 35. | Keller, H., Dreyer, C., Medin, J., Mahfoudi, A., Ozato, K., and Wahli, W. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2160-2164 |
| 36. | Desvergne, B., and Wahli, W. (1999) Endocr. Rev. 20, 649-688 |
| 37. | Spiegelman, B. M. (1998) Diabetes 47, 507-514 |
| 38. | Tontonoz, P., Hu, E. D., and Spiegelman, B. M. (1994) Cell 79, 1147-1156 |
| 39. | Bastie, C., Holst, D., Gaillard, D., JehlPietri, C., and Grimaldi, P. A. (1999) J. Biol. Chem. 274, 21920-21925 |
| 40. | Forman, B. M., Chen, J., and Evans, R. M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4312-4317 |
| 41. | Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., and Lehmann, J. M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4318-4323 |
| 42. | Krey, G., Braissant, O., L'Horset, F., Kalkhoven, E., Perroud, M., Parker, M. G., and Wahli, W. (1997) Mol. Endocrinol. 11, 779-791 |
| 43. | Wahli, W., Devchand, P. R., Upenberg, A., and Desvergne, B. (1999) Adv. Exp. Med. Biol. 447, 199-209 |
| 44. | Tontonoz, P., Hu, E. D., Devine, J., Beale, E. G., and Spiegelman, B. M. (1995) Mol. Cell. Biol. 15, 351-357 |
| 45. | Ren, B., Thelen, A., and Jump, D. B. (1996) J. Biol. Chem. 271, 17167-17173 |
| 46. | Ren, B., Thelen, A. P., Peters, J. M., Gonzalez, F. J., and Jump, D. B. (1997) J. Biol. Chem. 272, 26827-26832 |
| 47. | Pan, D. A., Mater, M. K., Thelen, A. P., Peters, J. M., Gonzalez, F. J., and Jump, D. B. (2000) J. Lipid Res. 41, 742-751 |
| 48. | Hertz, R., Magenheim, J., Berman, I., and Bar-Tana, J. (1998) Nature 392, 512-516 |
| 49. | Thurmond, D. C., Baillie, R. A., and Goodridge, A. G. (1998) J. Biol. Chem. 273, 15373-15381 |
| 50. | Worgall, T. S., Sturley, S. L., Seo, T., Osborne, T. F., and Deckelbaum, R. J. (1998) J. Biol. Chem. 273, 25537-25540 |
| 51. | Xu, J., Nakamura, M. T., Cho, H. P., and Clarke, S. D. (1999) J. Biol. Chem. 274, 23577-23583 |
| 52. | Mater, M. K., Thelen, A. P., Pan, D. A., and Jump, D. B. (1999) J. Biol. Chem. 274, 32725-32732 |
| 53. | Yahagi, N., Shimano, H., Hasty, A. H., Amemiya-Kudo, M., Okazaki, H., Tamura, Y., Iizuka, Y., Shionoiri, F., Ohashi, K., Osuga, J., Harada, K., Gotoda, T., Nagai, R., Ishibashi, S., and Yamada, N. (1999) J. Biol. Chem. 274, 35840-35844 |
| 54. | Shimano, H., Yahagi, N., Amemiya-Kudo, M., Hasty, A. H., Osuga, J., Tamura, Y., Shionoiri, F., Iizuka, Y., Ohashi, K., Harada, K., Gotoda, T., Ishibashi, S., and Yamada, N. (1999) J. Biol. Chem. 274, 35832-35839 |
| 55. | Roche, E., Buteau, J., Aniento, I., Reig, J. A., Soria, B., and Prentki, M. (1999) Diabetes 48, 2007-2014 |
| 56. | Tobin, K. A., Steineger, H. H., Alberti, S., Spydevold, O., Auwerx, J., Gustafsson, J. A., and Nebb, H. I. (2000) Mol. Endocrinol. 14, 741-752 |
| 57. | Abumrad, N., Harmon, C., and Ibrahimi, A. (1998) J. Lipid Res. 39, 2309-2318 |
This article has been cited by other articles:
![]() |
E. Karnieli and M. Armoni Transcriptional regulation of the insulin-responsive glucose transporter GLUT4 gene: from physiology to pathology Am J Physiol Endocrinol Metab, July 1, 2008; 295(1): E38 - E45. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Chen, P. H. Wang, B. H. Liu, H. H. Hsu, H. J. Mersmann, and S. T. Ding Serum Amyloid A Protein Regulates the Expression of Porcine Genes Related to Lipid Metabolism J. Nutr., April 1, 2008; 138(4): 674 - 679. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Kopec, D. R. Boverhof, L. D. Burgoon, D. Ibrahim-Aibo, J. R. Harkema, C. Tashiro, B. Chittim, and T. R. Zacharewski Comparative Toxicogenomic Examination of the Hepatic Effects of PCB126 and TCDD in Immature, Ovariectomized C57BL/6 Mice Toxicol. Sci., March 1, 2008; 102(1): 61 - 75. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.A. Paniagua, A. G. de la Sacristana, I. Romero, A. Vidal-Puig, J.M. Latre, E. Sanchez, P. Perez-Martinez, J. Lopez-Miranda, and F. Perez-Jimenez Monounsaturated Fat-Rich Diet Prevents Central Body Fat Distribution and Decreases Postprandial Adiponectin Expression Induced by a Carbohydrate-Rich Diet in Insulin-Resistant Subjects Diabetes Care, July 1, 2007; 30(7): 1717 - 1723. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Choi, M. Lee, A. L. Shiu, S. J. Yo, and G. W. Aponte Identification of a protein hydrolysate responsive G protein-coupled receptor in enterocytes Am J Physiol Gastrointest Liver Physiol, January 1, 2007; 292(1): G98 - G112. [Abstract] [Full Text] [PDF] |
||||
![]() |
R Buettner, K G Parhofer, M Woenckhaus, C E Wrede, L A Kunz-Schughart, J Scholmerich, and L C Bollheimer Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. J. Mol. Endocrinol., June 1, 2006; 36(3): 485 - 501. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Feng, G. Liu, G. Selvaraj, G. R. Hughes, and Y. Wei A secreted lipase encoded by LIP1 is necessary for efficient use of saturated triglyceride lipids in Fusarium graminearum Microbiology, December 1, 2005; 151(12): 3911 - 3921. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Armoni, C. Harel, F. Bar-Yoseph, S. Milo, and E. Karnieli Free Fatty Acids Repress the GLUT4 Gene Expression in Cardiac Muscle via Novel Response Elements J. Biol. Chem., October 14, 2005; 280(41): 34786 - 34795. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Le May, M. Cauzac, C. Diradourian, D. Perdereau, J. Girard, A.-F. Burnol, and J.-P. Pegorier Fatty Acids Induce L-CPT I Gene Expression through a PPAR{alpha}-Independent Mechanism in Rat Hepatoma Cells J. Nutr., October 1, 2005; 135(10): 2313 - 2319. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Boverhof, L. D. Burgoon, C. Tashiro, B. Chittim, J. R. Harkema, D. B. Jump, and T. R. Zacharewski Temporal and Dose-Dependent Hepatic Gene Expression Patterns in Mice Provide New Insights into TCDD-Mediated Hepatotoxicity Toxicol. Sci., June 1, 2005; 85(2): 1048 - 1063. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. I. Tsitsigiannis, T. M. Kowieski, R. Zarnowski, and N. P. Keller Endogenous Lipogenic Regulators of Spore Balance in Aspergillus nidulans Eukaryot. Cell, December 1, 2004; 3(6): 1398 - 1411. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. T. Lee, W.-Y. Chan, C. K. C. Lo, D. C. C. Wan, D. S. C. Tsang, and W.-T. Cheung Requirement of PPAR{alpha} in maintaining phospholipid and triacylglycerol homeostasis during energy deprivation J. Lipid Res., November 1, 2004; 45(11): 2025 - 2037. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-P. Pegorier, C. L. May, and J. Girard Control of Gene Expression by Fatty Acids J. Nutr., September 1, 2004; 134(9): 2444S - 2449S. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Benatti, G. Peluso, R. Nicolai, and M. Calvani Polyunsaturated Fatty Acids: Biochemical, Nutritional and Epigenetic Properties J. Am. Coll. Nutr., August 1, 2004; 23(4): 281 - 302. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kitajka, A. J. Sinclair, R. S. Weisinger, H. S. Weisinger, M. Mathai, A. P. Jayasooriya, J. E. Halver, and L. G. Puskas Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression PNAS, July 27, 2004; 101(30): 10931 - 10936. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. H. Huang, D. Gu, and T. Mazzone Oleic Acid Modulates the Post-translational Glycosylation of Macrophage ApoE to Increase Its Secretion J. Biol. Chem., July 9, 2004; 279(28): 29195 - 29201. [Abstract] [Full Text] [PDF] |
||||
![]() |
|